Reduction of arteriosclerotic nanoplaque formation and size by XXXX in a receptor-based biosensor model.

@entity1 @entity5470 @entity6 @entity535 @entity75 @entity61738 @entity3440 @entity460 @entity141 @entity597
@entity61738 can be adsorbed onto a methylated @entity3440 surface in a monomolecular layer via its transmembrane hydrophobic protein core domain. Due to electrostatic repulsion, its anionic glycosaminoglycan side chains are stretched out into the blood substitute solution, thereby representing a receptor site for specific lipoprotein binding through basic @entity535 -rich residues within their apolipoproteins. The binding process was studied by ellipsometric techniques suggesting that HDL has a high binding affinity and a protective effect on interfacial heparan @entity597 proteoglycan layers with respect to LDL and @entity141 complexation. LDL was found to be deposited strongly at the proteoheparan @entity597 -coated surface, particularly in the presence of @entity141 , apparently through complex formation 'proteoglycan-low density lipoprotein- @entity460 '. This ternary complex build-up may be interpreted as arteriosclerotic nanoplaque formation on the molecular level responsible for the @entity75 . In a receptor-based biosensor application, this system was tested on its reliability to unveil possible acute pleiotropic effects of the lipid lowering drug @entity5470 . The VLDL/IDL/LDL and VLDL/IDL/LDL/HDL plasma fractions from a high risk @entity1 with dyslipoproteinaemia and @entity6 showed the start of arteriosclerotic nanoplaque formation at a normal blood @entity141 concentration, with a strong increase at higher @entity141 concentrations. Nanoplaque formation and size of the HDL-containing lipid fraction remained well below that of the LDL-containing lipid fraction. @entity5470 , whether applied acutely to the @entity1 (one single 80 mg slow release matrix tablet) or in a 2-month medication regimen, markedly slowed down this process of ternary aggregational nanoplaque build-up and substantially inhibited nanoplaque size development at all @entity141 concentrations used. The acute action gave no significant change in lipid concentrations of the @entity1 . Furthermore, after nanoplaque generation, @entity5470 , similar to HDL, was able to reduce nanoplaque formation and size. These immediate effects of @entity5470 have to be taken into consideration when interpreting the clinical outcome of long-term studies.
